SixPeaks Debuts With Obesity Candidates And AstraZeneca Seal Of Approval
The start-up plans to enter the clinic next year with a muscle-sparing activin receptor IIA/B antibody, while AstraZeneca has an exclusive option to acquire the company.
The start-up plans to enter the clinic next year with a muscle-sparing activin receptor IIA/B antibody, while AstraZeneca has an exclusive option to acquire the company.